What is Micrima?
Founded in 2006, Micrima Ltd. operates at the intersection of medical physics and clinical diagnostics. The company specializes in the development of radio-wave imaging systems designed to detect breast cancer without the use of ionizing radiation or breast compression. By utilizing the dielectric properties of tissue, Micrima's technology provides a distinct diagnostic advantage, aiming to improve patient comfort and diagnostic precision. As a UK-based healthtech entity, Micrima maintains a strong focus on bridging the gap between academic research and clinical application, supported by a robust network of institutional and venture-backed partners.
How much funding has Micrima raised?
Micrima has raised a total of $14.2M across 3 funding rounds:
Unspecified
$3.4M
Private Equity
$5.6M
Unspecified
$5.2M
Unspecified (2016): $3.4M with participation from Technology Venture Partners, Angel CoFund, University of Bristol Enterprise Fund, and Swarraton Partners
Private Equity (2018): $5.6M led by Technology Venture Partners, Venture Founders, and Angel CoFund
Unspecified (2021): $5.2M supported by Technology Venture Partners LLC
Key Investors in Micrima
Technology Venture Partners
Technology Venture Partners is a firm operating within the Venture Capital and Private Equity sector, focusing on high-growth potential enterprises.
Angel CoFund
Angel CoFund is a specialized investment vehicle dedicated to supporting promising UK businesses through collaborative angel and co-investment strategies.
University of Bristol Enterprise Fund
The University of Bristol Enterprise Fund supports research-led innovation and commercialization of academic breakthroughs in medical and engineering sciences.
What's next for Micrima?
With the recent influx of capital, Micrima is well-positioned to scale its operational capabilities and navigate the complex regulatory pathways required for widespread clinical adoption. The strategic focus will likely shift toward expanding multi-center clinical trials and refining the diagnostic algorithms that power its radio-wave imaging platform. As the company matures, the emphasis will remain on establishing its technology as a standard-of-care alternative in breast screening, potentially disrupting traditional mammography markets. Investors are closely monitoring the company's ability to translate its technical milestones into tangible market share, particularly as the demand for patient-centric diagnostic tools continues to rise globally.
See full Micrima company page
